Cited by 4,816Advanced Drug Delivery Systemsbiodegradable polymer synthesis and propertiesNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 6 of the 116 sources its claims cite were checked for support.

Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier

Open access

Abstract

In past two decades poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications. PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mechanical properties and most importantly, is a FDA approved polymer. In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small molecule drugs, proteins and other macromolecules in commercial use and in research. This manuscript describes the various fabrication techniques for these devices and the factors affecting their degradation and drug release.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review surveys poly lactic-co-glycolic acid (PLGA) as a biodegradable controlled drug delivery carrier, covering its properties, copolymer systems, fabrication methods, release behavior, degradation factors, toxicology, and modeling. It concludes that PLGA is versatile and FDA-approved, with degradation and release tunable through composition, molecular weight, crystallinity, device geometry, and drug characteristics.

Key findings

  • PLGA is biocompatible, biodegradable, FDA-approved, and can be processed into nanospheres, microspheres, and millimeter-sized implants; it degrades by ester hydrolysis into lactic and glycolic acids, which are eliminated through normal metabolic routes or the kidney.
  • Degradation rate depends strongly on lactide-to-glycolide ratio: 50:50 PLGA degrades fastest, followed by 65:35, 75:25, and 85:15; higher glycolic acid content increases degradation, while higher molecular weight generally slows it. PLGA copolymers have a glass transition temperature above 37 °C and are glassy at physiological temperature.
  • Drug release is often biphasic, with an initial burst followed by slower diffusion and erosion; release is influenced by drug type and load, matrix surface-area-to-volume ratio, pH, crystallinity, and possibly enzymes, though reports on crystallinity and enzymatic degradation conflict.
  • Fabrication approaches include single and double emulsion, coacervation, spray drying, nanoprecipitation, salting out, solvent casting and compression molding, extrusion, supercritical CO₂ foaming, and multifunctional micro/nanoparticles; PLGA/PEG block copolymers can form thermogels but may reduce encapsulation efficiency.

Methods

  • Narrative review of prior literature; no experimental study, systematic search strategy, or primary data collection is described.
  • Synthesizes published work on PLGA physicochemical properties, pharmacokinetics and biodistribution, copolymer architectures, fabrication techniques, drug release behavior, degradation factors, toxicology, and mathematical modeling.
  • Includes equations for diffusion-controlled release, first-order molecular weight loss, and particle-size distributions such as Weibull or Rosin–Rammler models.

Limitations

  • The paper states that mechanisms of PLGA degradation and release are not clearly understood, that crystallinity effects are conflicting, that the role of enzymes is unresolved, and that in vivo and in vitro degradation rates often do not correlate well.
  • It notes that nanoscale PLGA may have distinct biodistribution and toxicological profiles, and that local tissue reactions at application sites can occur, though generally mild.
  • Evident from the text: as a narrative review, it lacks systematic search criteria, quality appraisal, and quantitative synthesis, so conclusions rest on selected cited studies rather than a formal evidence assessment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/polym3031377

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

6 of 116 cited sources checked · 3 supported · 0 flagged · accuracy not yet measured

Show all 53 claims

  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 27
42 of 42
  • The paper relies on this without support.

    A pulsated drug release profile is sometimes preferred over continuous drug presence because continuous presence may lead to receptor downregulation or tolerance development.

    “A pulsated drug release profile is sometimes preferred over the continuous presence of the drug, which may lead to downregulation of receptors or the development of tolerance.”
  • The paper relies on this without support.

    Large macroscopic formulations act as a drug reservoir that can be delivered over a longer interval.

    “Large size, macroscopic formulations act as a reservoir for drug that can be delivered over a longer interval.”
  • The paper relies on this without support.

    All microparticle preparation techniques described earlier can be employed for manufacturing PLGA nanoparticles by adjusting processing parameters.

    “All the above described microparticle techniques can be employed for manufacturing PLGA nanoparticles (nanospheres and nanocapsules) by adjusting the processing parameters.”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Opposite device-size trends for degradation

    Major

    The conclusion says a larger volume-to-surface ratio accelerates degradation, while Section 4.2.5 says a higher surface-area-to-volume ratio increases degradation. These ratios move in opposite directions.

  • PDLA and PLLA are described as physically alike and structurally unlike

    Minor

    The paper calls their physicochemical properties nearly the same, then describes PLLA as highly crystalline and PDLA as completely amorphous. Those are substantially different physical properties.

  • Opposite device-size ratios are said to accelerate degradation

    Minor

    The discussion says a higher surface-area-to-volume ratio increases degradation, while the conclusion says a larger volume-to-surface ratio accelerates it. Those ratios move in opposite directions.

  • The model reverses its boundary and initial-condition labels

    Minor

    Equation (3), called an initial condition, instead specifies concentration at the particle surface for times greater than zero. Equation (2), called a boundary condition, is restricted to time zero.

4 of 4

Citations

Cites

Flagged first, then by citations

Show all 98 references

Cited by

Sorted by citations

Items 1,501–1,600 of 4,778

Metadata

Authors
Makadia, H. K., & Siegel, S. J.
Affiliations
University of Pennsylvania (US)
Corresponding author
Siegel, Steven J.
Venue
Polymers
Publisher
MDPI AG
Published
2011-08-26
Volume
3
Issue
3
Pages
1377-1397
ISSN
2073-4360 (ISSN-L)
OpenAlex
W2087032263
Cited by
4,816
References
98
Citations by year
2026: 490 · 2025: 477 · 2024: 387 · 2023: 394 · 2022: 419 · 2021: 406 · 2020: 435 · 2019: 412 · 2018: 373 · 2017: 305 · 2016: 266 · 2015: 212 · 2014: 138 · 2013: 75 · 2012: 24
FWCI
46.54
Type
journal article
Language
en
Open access
Locations
  • Polymers (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institute of Mental Health (R01MH074672)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › biodegradable polymer synthesis and properties
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
poly(lactic-co-glycolic acid), PLGA, controlled drug delivery, biodegradable polymers, biocompatibility, drug release, polymer degradation, tissue engineering, small molecule drugs, protein delivery, macromolecule delivery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review